anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive darolutamide PO BID on days 1-28 of each cycle and leuprolide acetate IM every 4 or 12 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, collection of blood samples, and CT/MRI throughout the trial.
The present invention relates to a skin care composition comprising an extract of  Malva neglecta  and a cosmetically acceptable topical carrier. Non-polar and / or lipophilic extracts have been found to be particularly effective in improving skin barrier function, improving the appearance of at least one sign of aging in skin, and / or lightening skin. The composition may further comprise an agent, such as an active cosmetic agent, for further treating the skin condition. The present invention also relates to a method of treating a skin condition, particularly improving skin barrier function, improving the appearance of at least one sign of aging in skin, and / or lightening skin, by applying to the skin an extract of  Malva neglecta  topically to the skin in need of treatment. Topical application of non-polar and / or lipophilic extracts of  Malva neglecta  have been found to be particularly effective in improving skin barrier function, improving the appearance of at least one sign of aging in skin, and / or lightening skin. The extract may be applied in a composition further comprising an agent, such as an active cosmetic agent, for further treating the skin condition.
BACKGROUND: Primary ovarian insufficiency (POI) affects around 2-4% of women before the age of 40. Genetic factors play an important role in POI. The GDF9 gene has been identified as a significant genetic contributor of POI. However, the pathogenicity and penetrance of GDF9 variants remain uncertain.
METHODS: A next-generation sequencing approach was employed to investigate the entire coding region of the GDF9 gene in a cohort of 1281 patients with POI or diminished ovarian reserve (DOR). The frequency of each identified GDF9 variant was then compared with that of the general population, taking into account the ethnicity of each individual.
RESULTS: By screening the entire coding region of the GDF9 gene, we identified 19 different variants, including 1 pathogenic frameshift variant. In total, 36 patients with POI/DOR (2.8%) carried at least one GDF9 variant. With regard to missense variants, no significant overrepresentation of the most common variants was observed in our POI/DOR cohort in comparison to the general or specific ethnic subgroups. Only one homozygous subject had a frameshift loss of function variant.
CONCLUSION: This epidemiological study suggests that the vast majority of heterozygous missense variants could be considered as variants of uncertain significance and the homozygous loss-of-function variant could be considered as a pathogenic variant. The identification of a novel case of a homozygous POI patient with a heterozygous mother carrying the same variant with normal ovarian function strongly suggests that GDF9 syndrome is an autosomal recessive disorder.
OBJECTIVE: Data on cardiovascular outcomes according to objectively measured physical activity (PA) in patients with atrial fibrillation (AF) are scarce. This study explored the associations between PA derived from wrist-worn accelerometers and the risk of death, incident heart failure (HF), and incident stroke in patients with AF.
METHODS: From 37 990 patients with AF in UK Biobank, 2324 patients with accelerometer data were included. Weekly moderate-to-vigorous PA (MVPA) duration was computed from accelerometer data. The primary outcome was all-cause mortality. Secondary outcomes were cardiovascular mortality, incident HF, and incident stroke. Restricted cubic splines estimated the dose-response associations between MVPA duration and the outcomes. The adjusted HRs (aHRs) of the outcomes according to adherence to PA standard guidelines (performing MVPA≥150 min/week) were also evaluated.
RESULTS: The mean age was 66.9±6.2 years and 64.9% were male. During a median follow-up of 6.7 years, there were 181 all-cause deaths, 62 cardiovascular deaths, 225 cases of incident HF, and 91 cases of incident stroke; the overall incidence rate per 1000 patient-years was 11.76, 4.03, 15.16 and 5.99, respectively. There was a linear inverse dose-response relationship between MVPA (≥108 min/week) and all-cause mortality. Performing MVPA for 105-590 min/week was associated with a lower risk of HF than those with no measurable MVPA. The risk of stroke and cardiovascular mortality was not associated with MVPA. Performing guideline-adherent MVPA was related to a 30% lower risk of all-cause mortality (aHR: 0.70 (0.50-0.98), p=0.04) and 33% lower risk of HF (aHR 0.67 (0.49-0.93), p=0.02).
CONCLUSION: In patients with AF, accelerometer-derived PA data supports lower risks of all-cause mortality and HF according to a greater level of MVPA and adherence to PA guidelines. Regular MVPA should be encouraged in patients with AF as a part of integrated management.
PROBLEM TO BE SOLVED: To obtain the subject new compound having a fruity fragrance with a voluminous feeling and useful as a perfuming ingredient for toiletry articles such as a soap, a shampoo, a rinse, a detergent or a cosmetic. SOLUTION: This compound is represented by formula I (R1 to R6 are each H, methyl or ethyl; and the total number of carbon atoms in R1 to R6 is <=3), e.g. a compound represented by formula II. The compound represented by formula I is obtained by reacting an alkylcyclohexenone represented by formula III with 2-methyl-1-propenylmagnesium bromide in the presence of a copper catalyst, e.g. a copper halide (e.g. copper iodide), providing a compound represented by formula IV, then reacting the resultant compound represented by formula IV with water, methanol or ethanol in the presence of an acidic catalyst such as sulfuric acid or p-toluenesulfonic acid.  The compound represented by formula I is contained in an amount of preferably 0.1-90 wt.% in a compound perfume to thereby obtain a composition having mainly fruity fragrances and various fragrances such as a green, a pearlike or a helional-like fragrance.
BACKGROUND: Individuals who are living with obesity often adopt alternative lower limb walking mechanics compared to persons with a healthy weight. Stair negotiation is a common activity of daily living that, when used consistently with diet and other physical activity, can help promote the reversal of health-related risk factors associated with people who are obese. The purpose of this study was to determine how stair negotiation affects normalized and non-normalized peak knee extension and abduction moments in young adults who live with obesity (BMI between 30 and 40 kg/m2) compared to adults with a healthy weight (BMI between 18.5 and 25 kg/m2).
METHODS: Fifteen young adults living with obesity and fifteen with a healthy weight performed stair ascent and descent walking trials on a 3-step instrumented staircase at a self-selected walking speed. A one-way ANCOVA (covariate: gait speed) was used to compare knee moment variables between groups.
RESULTS: No significant differences were found between groups in peak knee joint moments normalized to body mass. The individuals living with obesity demonstrated significantly larger non-normalized peak knee extension moments during stair ascent and descent but no differences in the non-normalized peak knee abduction moments for stair ascent or descent.
CONCLUSION: Results of this study indicate differences in non-normalized peak knee extension moments between BMI groups. The young age of the obese group may have contributed to minimal differences overall. Future research should determine how these findings differ in an older obese population and how using a handrail would affect these results.
FIELD: ion-exchange purification methods. SUBSTANCE: regeneration of styrene-divinylbenzene-based anionites with quaternary ammonium base groups is used when preparing biologically-active compounds and in various national economy areas involving strong-base anionite purification operations, e.g. in wine making, sugar industry, etc. Prolongation of lifetime of strong-base anionites in heparin and canamicin production is achieved by that, anionite, after target product is desorbed, is regenerated by sodium hypochlorite solution. Big organic molecules irreversibly captured by anionite, are destroyed by oxidant into small fragments that are then easily washed away by water. EFFECT: prolonged anionite lifetime. 3 dwg, 2 tbl
A medical device and displacement-based over-pressurization mechanism (OPM) for use with the same. The OPM may be positioned in or along a refill passageway of the device. It may include a valve plunger having a portion in biased, abutting contact with a reservoir surface that moves as the reservoir volume changes. The reservoir surface may move between a full position and a refill position. The OPM is preferably configured to close and occlude the refill passageway when the reservoir and reservoir surface reach the full position, e.g., before reaching an overfill position. A sensor may also be provided to detect a position of the valve plunger.
BACKGROUND: Fatigability in community-dwelling older adults is highly prevalent and disabling, but lacks a treatment. Greater nigrostriatal dopaminergic signaling can ameliorate performance fatigability in healthy young adults, but its role in community-dwelling older adults is not known. We hypothesized that higher nigrostriatal dopaminergic integrity would be associated with lower performance fatigability, independent of cardiopulmonary and musculoskeletal energetics and other health conditions.
METHODS: In 125 older adults participating in the Study of Muscle, Mobility and Aging, performance fatigability was measured as performance deterioration during a fast 400 m walk (% slowing down from the 2nd to the 9th lap). Nigrostriatal DA integrity was measured using (+)-[11C] dihydrotetrabenazine (DTBZ) PET imaging. The binding signal was obtained separately for the subregions regulating sensorimotor (posterior putamen), reward (ventral striatum), and executive control processes (dorsal striatum). Multivariable linear regression models of performance fatigability (dependent variable) estimated the coefficients of dopamine integrity in striatal subregions, adjusted for demographics, comorbidities, and cognition. Models were further adjusted for skeletal muscle energetics (via biopsy) and cardiopulmonary fitness (via cardiopulmonary exercise testing).
RESULTS: Higher [11C]-DTBZ binding in the posterior putamen was significantly associated with lower performance fatigability (demographic-adjusted standardized β = -1.08, 95% CI: -1.96, -0.20); results remained independent of adjustment for other covariates, including cardiopulmonary and musculoskeletal energetics. Associations with other striatal subregions were not significant.
DISCUSSION: Dopaminergic integrity in the sensorimotor striatum may influence performance fatigability in older adults without clinically overt diseases, independent of other aging systems.
A pharmaceutical composition. The composition has a plurality of controlled release particulates. Each particulate includes a coating layer and a core partially coated with the coating layer, in which the core contains a water-insoluble drug 5-80 wt. % and a first polymer 0.2-80 wt. % and the coating layer contains the water-insoluble drug 0-50 wt. % and a second polymer 0.2-50 wt. %. Each of the first and second polymers, independently, is a water-insoluble polymer, an enteric polymer, or a combination thereof. A method of making the composition is also disclosed herein.
ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. No meaningful effect was demonstrated for generalized erythema (redness) of rosacea. ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea. Efficacy of ORACEA beyond 16 weeks and safety beyond 9 months have not been established.

This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. ORACEA should not be used for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease.

To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ORACEA should be used only as indicated.
The present invention generally relates to novel protein domains which bind to tyrosine-phosphorylated proteins. More particularly, the present invention provides non-SH2 protein domains that bind phosphotyrosine. The present invention also provides various composite polypeptides comprising these domains, such that these composite polypeptides retain the ability to bind tyrosine phosphorylated proteins. It also provides nucleic acids encoding these polypeptides. Typically, these nucleic acids may also comprise a promoter for expression, and a segment encoding fusion peptides on the amino or carboxy terminus of the expressed composite protein. Also included within the present invention are methods of preparing these polypeptides and cells capable of expressing them. Also provided are methods of using these polypeptides in research, diagnostic and therapeutic applications.
Asthma prevalence has steadily increased in the United States since the early 1980s, with infants and young children showing the largest increase. Some young children experience wheezing, but it is not known if this is related specifically to asthma. Wheezing may be caused by a respiratory syncytial virus, maternal smoking, a family history of asthma, or allergies. In addition, some infants who experience wheezing may have small or dysfunctional airways and may not respond well to commonly prescribed anti-inflammatory medications. Because of the many causes of wheezing, in order to prescribe the most effective treatment, it is necessary to thoroughly assess lung function, allergic sensitization, and airway inflammation. The purpose of this study is to examine the causes of moderate to severe wheezing in infants and assess the infants' response to inhaled corticosteroid therapy. The study will also assess new and safer ways to measure lung function and airway inflammation.

This study will enroll infants with moderate to severe persistent wheezing. At study entry, participants will undergo lung function testing, which will include a spirometry test, measures of lung volumes, and assessment of bronchodilator responsiveness. Exhaled breath condensate and blood will be collected, and skin-prick testing will be performed to test for allergies. Participants will then be randomly assigned to receive either fluticasone, an inhaled steroid, or placebo for one month. At the end of the month, lung function testing will be performed and exhaled breath and serum measures will be collected to assess airway inflammation. Participants will attend a follow-up evaluation at age 5 years. During the evaluation, lung function, exhaled breath condensate, and serum markers of inflammation will be measured again, and skin-prick testing will also be performed again.
BACKGROUND: Impairments in voice quality in Multiple Sclerosis (MS) have recently been investigated and different results were found. A voice-centered multidimensional assessment protocol with patient-reported outcome measures was conducted to evaluate all the aspects of the voice changes.
OBJECTIVES: The study aimed to compare the objective, subjective, and perceptual measures of voice between the people with MS and the healthy control group.
METHODS: A total of 128 participants, including 64 people with MS age, and gender-matched healthy controls were enrolled in the study. Subjective, objective, and auditory-perceptual voice assessments of the participants were performed. The auditory-perceptual evaluation was performed with GRBAS. The Dysphonia Severity index was computed for both groups. All the participants completed the Turkish version of The Voice Handicap Index-10 (VHI-10) and the Voice-Related Quality of Life (VRQoL).
RESULTS: Acoustic and aerodynamic parameters of voice were found significantly different for both males and females between the MS and control group. DSI was found significantly different for both males and females in the MS group compared to the control group (p<0.05). All components of the GRBAS scale were significantly higher in the MS group (p<0.001). Using a multivariate regression model, it was determined that age, gender, EDSS score, number of MS attacks, and disease duration did not affect the DSI. The overall VHI-10 score was higher in the MS group (median=1.0 range= 0-28) and lower in the control group (median=0 range= 0-4). The mean VRQoL was lower in the MS group (median=95 range= 62.5-100) than in controls (median=100 range= 85-100) (p<0.001).
CONCLUSION: Our results indicated that people with MS have significant differences in acoustic and aerodynamic parameters of voice compared to healthy individuals. A significant number of persons with MS are aware that their voice problem affects their quality of life. People with MS must be monitored for voice changes and a multidimensional voice assessment protocol should be implemented.
Following previous research, our hypothesis is that infants in the experimental group will display significantly more positive scores on a collection of physiological and behavioural measurements. The stimuli used at each age will be targeted to the infants' developmental level. Bayley Scales of Infant Development will also be administered at 18 - 24 months as part of high risk infant follow up. These data will be included in the analysis for outcome measurement. While seated in a high-chair or their parent's lap, infants will be habituated to a series of images of a particular shape (e.g., a triangle), while their looking time to each stimulus is measured. Each image during habituation will be a unique token of the category (i.e., all different triangles). Habituation will be individually determined, and defined as cumulative looking across three successive trials that is 50% than cumulative looking across the first three trials. Following habituation, infants will be shown a novel token of the habituation shape (e.g., a new triangle) and a novel shape (e.g., a square), in counterbalanced order. If infants recognize the category change, they should look longer at novel category compared to the novel token. For each test, two dependent measures will be sampled: rate of habituation and amount of dishabituation to the novel category. Mixed ANOVA and paired t-tests will be used to analyze the data. As preterm infants have been shown to be delayed on these kinds of tasks, we hypothesize that the experimental group will habituate to each category faster, and/or display stronger dishabituation scores compared to the preterm. We will also use multiple regression analyses to examine relations between the NICU physiological and behavioural measures and the cognitive measures. We hypothesize that infants who most strongly benefited from their therapies in the NICU will display the most advanced cognitive abilities. An intention-to-treat- analysis will be performed for cognitive measures as well. The cognitive assessment at 2 and 4 months that were to be carried out at the Developmental Lab at University of Regina is now canceled due to feasibility concerns.
Residential school children aged 5-12 yrs at high risk for caries. A total of 36 children will be recruited for the study and randomly divided into 3 groups with 12 participants per group.The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
PURPOSE: To obtain a new compound having a protease inhibiting activity, especially HIV protease inhibiting activity by an intramolecular shift at a physiological pH, useful as a prodrug of a peptide derivative. CONSTITUTION: This prodrug is a compound expressed by formula I (Ph is phenyl; t-Bu is tert-butyl; R is methylthiomethyl, methanesulfonylmethyl or carbamoylmethyl, etc.; X is C or S atom; Y is 1-naphthyl or 5-isoquinolyl; (n) is 0 or 1) or its pharmacologically permissible salt such as a compound expressed by formula II. A compound of the formula I is e.g. obtained from a compound expressed by formula III (Z is benzyloxycarbonyl) as a starting material. The compound of the formula I is transformed to a peptide derivative of the formula IV in an aqueous solution to manifest the HIV protease inhibiting activity.
A wool product for use in the disposal of faeces in the environment comprising wool fibres and a treatment composition, and a method of treatment of raw wool to produce the wool product are described. The treatment composition comprises a probiotic, the probiotic comprises at least one non-pathogenic species of Bacteria, and the wool fibres are at least partially coated with the treatment composition. The wool may be treated prior to application of the bacteria, to remove lanolin. Preferably the bacteria is at least one non-pathogenic species of Bacillus, lactobacillus, Lactococcus, Bifidobacterium, Azospirillum, Enterobacter, Klebsiella, Pseudomonas, Sphingomonas, Nitrospira, Pedomicrobium, Mycobacterium, Nocardia and Desulfovibrio. Most preferably the Bacillus subtilis, Bacillus licheniformis, Bacillus megaterium, Bacillus amyloliquefaciens, Bacillus pumilus. The composition preferably comprises at least one of a fructo-oligosaccharide, a galacto-oligosaccharide and inulin.
OBJECTIVE: To explore the clinical phenotype and genetic variant in a Chinese pedigree affected with Hunter syndrome and create immortalized cell lines for the affected pedigree members.
METHODS: A pedigree of six members who had visited Xi'an Children's Hospital in July 2022 was selected as the study subject. Clinical data was collected. Whole exome sequencing was carried out for the pedigree members. Candidate variant was verified by Sanger sequencing. In addition, peripheral B lymphocytes were transfected with Epstein-Barr virus to create immortalized cell lines, which were then subjected to enzyme activity analysis.
RESULTS: The patient, a five-year-and-seven-month-old boy, had exhibited stiff limbs and enlarged joints. He had developed hernia, scaphocephaly, and barrel chest from 3 months of age. His uncle also had stiff limbs, poor hearing, blindness, and right oblique inguinal hernia. Above features had resembled those of Hunter syndrome. Genetic testing revealed that both the child and his uncle had harbored an IDS (NM_000202.8): c.823G>A (p.D275N) variant, which was unreported previously. Bioinformatic analysis indicated that the D275 to be a highly conserved site, and the D275N variant may affect the stability of the protein's spatial conformation, thereby decrease the catalytic activity of the enzyme. The successfully constructed immortalized lymphoblastoid cell lines for the child and his parents showed increased volume, irregular shape, burr structure and cluster growth. And the value of IDS activity of the patient's immortalized lymphoblastoid cells was below the limit of detection. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG), the variant was classified as likely pathogenic (PS3+PM2_Supporting+PM5+PP1+PP3).
CONCLUSION: Above finding has enriched the phenotypic and mutational spectra of Hunter syndrome, and provided a basis for the genetic counseling for this pedigree. The creation of immortalized cell lines has offered a model for further investigation of the impact of variant on the function of IDS and development of targeted drugs.